---

Highlights of March 2020

1. India’s Curadev signs US$267 Million pact with Bayer for novel STING antagonists across indications.
2. Curadev has completed 4 licensing, multi-million dollar deals with companies like Roche, Takeda, and Bayer, in the last 4.5 years, while being just 10 year young company.
3. Pune, India-based Mylab gets commercial approval for first ‘Made in India’ test kit for COVID-19. It will be priced at only ~US$15 per test kit.
4. Zydus Healthcare and XOMA Announce IL-2-Based Immuno-Oncology Therapy Licensing Agreement.
5. Cipla to manufacture anti-viral drugs eyeing Covid containment.
6. HUL to acquire hygiene brand VWash from Glenmark Pharma.
7. Ahmedabad based CoSara Diagnostics Pvt Ltd, has received a license from the Central Drugs Standards Control Organisation (CDSCO) to manufacture RT-PCR COVID-19 test kits.
8. Sitryx snags a potential US$880 Million deal on new immune-metabolic medicines.
9. Biogen puts down massive US$350 Million upfront for Sangamo preclinical assets.
10. CG Oncology could get US$110 million in deal with Kissei for CG0070.
11. Norgine acquires Danish firm Azanta.
12. Pfizer, BioNTech strike COVID-19 deal, commit multiple R&D sites to vaccine development.

Highlights at Aagami

• New Client Win: Singapore based Cancer healthcare and data science company has chosen Aagami to support their investment and partnering needs.
• Aagami and their Australian client reach favorable term sheet level discussions with a Large Pharma for a strategic US$ 20M+ deal with a high potential to expand into much more.
• Our Business associate ‘Sagacious IP’ is Offering 1,000 Hours of Complimentary Research Assistance to the Global Researchers working on prevention / cure for COVID-19. Aagami has partnered to contribute in getting this valuable assistance available to the Research Fraternity.
• More details and an initial report about current COVID-19 treatment, etc. is available at: https://www.sagaciousresearch.com/coronavirus-research-assistance

Some of the partnering opportunities available at Aagami are:

1. For IP Acquisition: Next-Generation PEGylation (PharmaPEG®) technology & associated assets.
2. Seeking Investor: Drug-device to delay the progression of Parkinson’s disease (PD), prevent Asian Flush and hangover.
3. For Licensing: Selection Technology using Bacteriocin-Immunity for Improved Microbial (E. coli.) Fermentation.
4. In-License - Highly Effective Bioremediation of Oil Spills. The Bioremediation products based on patented Biodispersion process.